🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s LXEO Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+114,322 Shares
Current Position
114,322 Shares
$532,168 Value

Ken Fisher's LXEO Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 114,322 shares of Lexeo Therapeutics, Inc. (LXEO) worth $532,168, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in LXEO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Lexeo Therapeutics (LXEO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Lexeo Therapeutics (LXEO) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +114,322 New Buy 114,322 $4.65

Ken Fisher's Lexeo Therapeutics Investment FAQs

Ken Fisher first purchased Lexeo Therapeutics, Inc. (LXEO) in Q2 2026, acquiring 114,322 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Lexeo Therapeutics, Inc. (LXEO) for 1 quarters since Q2 2026.

Ken Fisher's largest addition to Lexeo Therapeutics, Inc. (LXEO) was in Q2 2026, adding 114,322 shares worth $532,168.

According to the latest 13F filing for Q2 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 114,322 shares of Lexeo Therapeutics, Inc. (LXEO), valued at approximately $532,168.

As of the Q2 2026 filing, Lexeo Therapeutics, Inc. (LXEO) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Lexeo Therapeutics, Inc. (LXEO) was 114,322 shares, as reported at the end of Q2 2026.